Indonesia Gram Negative Infection Therapeutics Market Report 2023 to 2030

Indonesia Gram-Negative Infection Therapeutics Market Analysis

$ 3999

The Indonesia Gram-Negative Infection Therapeutics Market was valued at $89.2 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $133.3 Mn by 2030. The main factors driving this market expansion include the rising prevalence of hospital-acquired infections (HAIs), increased demand due to the widespread overuse and misuse of antibiotics, and a fragmented healthcare system. Leading companies in this market in Indonesia include Kalbe Farma and Bio Farma, among others.

ID: IN10IDPH563 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Aryan Patel

Buy Now

Indonesia Gram-Negative Infection Therapeutics Market Executive Summary

The Indonesia Gram-Negative Infection Therapeutics Market was valued at $89.2 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $133.3 Mn by 2030.

Gram-negative bacteria are classified based on their cell wall structure and staining characteristics. They have a thin peptidoglycan cell wall and an outer membrane containing lipopolysaccharides. This unique structure makes them resistant to certain antibiotics and allows them to release endotoxins when disrupted. Gram-negative bacteria are characterized by their ability to stain pink or red under a microscope due to their lack of retention of the crystal violet dye used in gram staining. They are diverse, including pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. These bacteria cause various infections, including pneumonia, sepsis, urinary tract infections, and wound infections, particularly in hospital settings.

Indonesia has a significant disease burden. The overall prevalence of HAIs in Southeast Asia is 21.6%, with Indonesia having the highest rate. Most of the HAIs in Indonesia are caused by gram-negative bacteria. Factors like increasing hospital-acquired infections (HAIs), rising demand due to widespread antibiotic overuse and misuse, and a fragmented healthcare system drive the market growth, whereas the lack of new therapies, limited healthcare infrastructure, and cost containment measures retrain the market.

Indonesia Gram Negative Infection Therapeutic Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Hospital-Acquired Infections (HAIs): The overall prevalence of HAIs in Southeast Asia is 21.6%, with Indonesia having the highest rate. Limited resources for infection control measures further exacerbate the problem, further fuelling the demand for therapeutics.

Increase in demand due to widespread antibiotic overuse and misuse: The overuse and misuse of antibiotics, including easy access without prescription, has contributed to the growth of antimicrobial resistance (AMR) in Indonesia. This has created an urgent need for new antibiotics effective against drug-resistant gram-negative pathogens, thus increasing demand and driving the market.

Fragmented Healthcare System: Indonesia's decentralized public healthcare system with variable access to quality care has made the country vulnerable to AMR and infectious disease burdens. The lack of access to quality healthcare, vaccination, safe water, and sanitation leaves many susceptible to infection and dependent on antibiotics, thus driving the market.

Market Restraints

Lack of New Therapies: There is a lack of new antibiotics with novel mechanisms of action that are effective against drug-resistant gram-negative infections, which have high mortality rates. Despite the launch of some new antibiotics, the market remains heavily genericized, and cost-containment measures have limited the commercial success of new therapies, thus restraining the market.

Limited Healthcare Infrastructure: Indonesia's decentralized public healthcare system with variable access to quality care exacerbates the issue of AMR and infectious disease burdens, making it difficult to treat and manage gram-negative infections effectively, restraining market growth.

Cost Containment Measures: The market is heavily genericized, and cost-containment measures have limited the commercial success of new therapies, making it challenging for companies to invest in research and development of new treatments. This financial pressure makes it challenging for companies to invest in the research and development of new treatments, further restraining market expansion.

Regulatory Landscape and Reimbursement Scenario

The National Agency of Drug and Food Control (BPOM/NADFC) is the primary regulatory body responsible for guaranteeing the safety, quality, and effectiveness of pharmaceuticals in Indonesia. BPOM oversees the review process of drug registration applications and issues marketing authorizations as drug approvals, coordinating with the Ministry of Health (MOH) regarding regulatory affairs concerning drugs and pharmaceuticals.

The reimbursement scenario for gram-negative infection therapeutics in Indonesia involves a complex landscape with multiple players and factors influencing coverage. The BPOM and MOH regulate the market, while the Health Social Security Agency (BPJS) and the National Health Insurance (JKN) program are responsible for reimbursement. Companies must demonstrate the value proposition of their drugs, including clinical effectiveness and cost-effectiveness, to secure inclusion in the JKN formulary.

The reimbursement scenario is tiered, with full reimbursement for highly effective drugs targeting critical MDR infections, limited reimbursement for specific hospitals or patient groups based on cost considerations, and no initial reimbursement for costly drugs.

Competitive Landscape

Key Players

Here are some of the major key players in the Indonesia Gram-Negative Infection Therapeutics Market:

Kalbe Farma
Bio Farma
GlaxoSmithKline plc (GSK)
Pfizer Inc.
Sanofi-Aventis
Takeda Pharmaceutical Company Limited
Nektar Therapeutics
Baxter
Novartis
Sumitomo

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Indonesia Gram-Negative Infection Therapeutics Market Segmentation

By Drug Types

Antibiotics
Combination Therapies
Adjunctive Therapies

By Infection Types

Urinary Tract Infections (UTIs)
Pneumonia
Bloodstream Infections (Bacteraemia)
Wound/Surgical Site Infections
Gastrointestinal Infections
Meningitis
Hospital-Acquired Infections (HAIs)
Respiratory Tract Infections (RTIs)
Other Infections

By Route of Administration

Oral
Parenteral (injections, intravenous)
Topical

By Distribution Channel

Hospitals
Clinics
Ambulatory Surgical Centres
Home Healthcare
Long-term Care Facilities
Community Health Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.